News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
News Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e... Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it
News Amgen pays Kyowa $400m upfront for OX40 eczema drug Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.